1296P - Radical treatment of non-small cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (NCT012...

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Surgery and/or Radiotherapy of Cancer
Presenter Dirk De Ruysscher
Authors D. De Ruysscher1, R. Wanders2, A. van Baardwijk2, A.C. Dingemans3, B. Reymen2, G. Bootsma4, C. Pitz5, W. Geraedts6, B. Baumert2, P. Lambin2
  • 1Radiation Oncology, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 2Maastro Clinic, Maastricht University Medical Center (MUMC), 6202 AZ - Maastricht/NL
  • 3Pulmonology, Maastricht University Medical Center (MUMC), NL-6202 AZ - Maastricht/NL
  • 4Pulmonology, Atrium Medical Center Heerlen, Heerlen/NL
  • 5Pulmonology, Laurentius Hospital, Roermond/NL
  • 6Pulmonology, Orbis MC, Sittard/NL



Stage IV non-small cell lung cancer (NSCLC) patients with oligometastases (< 5 metastatic lesions) may experience long-term survival when all macroscopic tumour sites are treated radically, but no prospective data on NSCLC with synchronous metastases are available.


Prospective single-arm phase II trial. Main inclusion criteria: pathological proven NSCLC stage IV with less than 5 metastases at primary diagnosis, amendable for radical local treatment (surgery or radiotherapy). The study is listed in clinicaltrials.gov number NCT01282450.


39 patients (18 males, 21 females) with a mean age of 62.1 ± 9.2 years, range 44-81) were analysed. 29 (74 %) had “local” stage III; 17 (44 %) brain, 7 (18 %) bone and 4 (10 %) adrenal gland metastases. 34 (87 %) had a single metastatic lesion. 37 (95 %) of patients received chemotherapy as part of their primary treatment. Median overall survival (OS) was 13.5 months (95 % CI 7.6-19.4); 1-, 2- and 3-year OS 56.4 %, 23.3 % and 17.5 %, respectively. Median progression-free survival (PFS) was 12.1 months (95 % CI 9.6-14.3); 1-year PFS was 51.3 %, both 2- and 3 year PFS 13.6 %. Only 2 patients (5 %) had a local recurrence. No patient or tumour parameter, including volume and FDG uptake was significantly correlated with OS or PFS. The treatment was well tolerated.


In this phase II study, long-term PFS was found in a subgroup of NSCLC patients with synchronous oligometastases when treated radically. Identification of this favourable subgroup before therapy is needed.


All authors have declared no conflicts of interest.